These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 17566112)

  • 1. Effect of subcutaneous injections of PYY1-36 and PYY3-36 on appetite, ad libitum energy intake, and plasma free fatty acid concentration in obese males.
    Sloth B; Davidsen L; Holst JJ; Flint A; Astrup A
    Am J Physiol Endocrinol Metab; 2007 Aug; 293(2):E604-9. PubMed ID: 17566112
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of PYY1-36 and PYY3-36 on appetite, energy intake, energy expenditure, glucose and fat metabolism in obese and lean subjects.
    Sloth B; Holst JJ; Flint A; Gregersen NT; Astrup A
    Am J Physiol Endocrinol Metab; 2007 Apr; 292(4):E1062-8. PubMed ID: 17148749
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of PYY3-36 and GLP-1 on energy intake, energy expenditure, and appetite in overweight men.
    Schmidt JB; Gregersen NT; Pedersen SD; Arentoft JL; Ritz C; Schwartz TW; Holst JJ; Astrup A; Sjödin A
    Am J Physiol Endocrinol Metab; 2014 Jun; 306(11):E1248-56. PubMed ID: 24735885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of peptide YY3-36 on food intake in humans.
    Degen L; Oesch S; Casanova M; Graf S; Ketterer S; Drewe J; Beglinger C
    Gastroenterology; 2005 Nov; 129(5):1430-6. PubMed ID: 16285944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peptide YY3-36 and glucagon-like peptide-17-36 inhibit food intake additively.
    Neary NM; Small CJ; Druce MR; Park AJ; Ellis SM; Semjonous NM; Dakin CL; Filipsson K; Wang F; Kent AS; Frost GS; Ghatei MA; Bloom SR
    Endocrinology; 2005 Dec; 146(12):5120-7. PubMed ID: 16150917
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute administration of capsaicin increases resting energy expenditure in young obese subjects without affecting energy intake, appetite, and circulating levels of orexigenic/anorexigenic peptides.
    Rigamonti AE; Casnici C; Marelli O; De Col A; Tamini S; Lucchetti E; Tringali G; De Micheli R; Abbruzzese L; Bortolotti M; Cella SG; Sartorio A
    Nutr Res; 2018 Apr; 52():71-79. PubMed ID: 29530622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential effect of PYY1-36 and PYY3-36 on gastric emptying in man.
    Witte AB; Grybäck P; Holst JJ; Hilsted L; Hellström PM; Jacobsson H; Schmidt PT
    Regul Pept; 2009 Nov; 158(1-3):57-62. PubMed ID: 19651163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of food intake in obese subjects by peptide YY3-36.
    Batterham RL; Cohen MA; Ellis SM; Le Roux CW; Withers DJ; Frost GS; Ghatei MA; Bloom SR
    N Engl J Med; 2003 Sep; 349(10):941-8. PubMed ID: 12954742
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans.
    Verdich C; Flint A; Gutzwiller JP; Näslund E; Beglinger C; Hellström PM; Long SJ; Morgan LM; Holst JJ; Astrup A
    J Clin Endocrinol Metab; 2001 Sep; 86(9):4382-9. PubMed ID: 11549680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Free fatty acids have more potent effects on gastric emptying, gut hormones, and appetite than triacylglycerides.
    Little TJ; Russo A; Meyer JH; Horowitz M; Smyth DR; Bellon M; Wishart JM; Jones KL; Feinle-Bisset C
    Gastroenterology; 2007 Oct; 133(4):1124-31. PubMed ID: 17919488
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity.
    Blundell J; Finlayson G; Axelsen M; Flint A; Gibbons C; Kvist T; Hjerpsted JB
    Diabetes Obes Metab; 2017 Sep; 19(9):1242-1251. PubMed ID: 28266779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PYY3-36 and oxyntomodulin can be additive in their effect on food intake in overweight and obese humans.
    Field BC; Wren AM; Peters V; Baynes KC; Martin NM; Patterson M; Alsaraf S; Amber V; Wynne K; Ghatei MA; Bloom SR
    Diabetes; 2010 Jul; 59(7):1635-9. PubMed ID: 20357366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of postprandial profiles of ghrelin, active GLP-1, and total PYY to meals varying in fat and carbohydrate and their association with hunger and the phases of satiety.
    Gibbons C; Caudwell P; Finlayson G; Webb DL; Hellström PM; Näslund E; Blundell JE
    J Clin Endocrinol Metab; 2013 May; 98(5):E847-55. PubMed ID: 23509106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pulmonary delivery of peptide YY for food intake suppression and reduced body weight gain in rats.
    Nadkarni PP; Costanzo RM; Sakagami M
    Diabetes Obes Metab; 2011 May; 13(5):408-17. PubMed ID: 21226821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of a single dose of exenatide on appetite, gut hormones, and glucose homeostasis in adults with Prader-Willi syndrome.
    Sze L; Purtell L; Jenkins A; Loughnan G; Smith E; Herzog H; Sainsbury A; Steinbeck K; Campbell LV; Viardot A
    J Clin Endocrinol Metab; 2011 Aug; 96(8):E1314-9. PubMed ID: 21632815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhaled PYY(3-36) dry-powder formulation for appetite suppression.
    Kuehl PJ; Boyden T; Dobry DE; Doyle-Eisele M; Friesen DT; McDonald JD; Murri BG; Vodak DT; Lyon DK
    Drug Dev Ind Pharm; 2016 Jan; 42(1):150-156. PubMed ID: 26006332
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of peripheral administration of PYY3-36 on feed intake and plasma acyl-ghrelin levels in pigs.
    Ito T; Thidarmyint H; Murata T; Inoue H; Neyra RM; Kuwayama H
    J Endocrinol; 2006 Oct; 191(1):113-9. PubMed ID: 17065394
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Orlistat inhibition of intestinal lipase acutely increases appetite and attenuates postprandial glucagon-like peptide-1-(7-36)-amide-1, cholecystokinin, and peptide YY concentrations.
    Ellrichmann M; Kapelle M; Ritter PR; Holst JJ; Herzig KH; Schmidt WE; Schmitz F; Meier JJ
    J Clin Endocrinol Metab; 2008 Oct; 93(10):3995-8. PubMed ID: 18647814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gut hormone PYY(3-36) physiologically inhibits food intake.
    Batterham RL; Cowley MA; Small CJ; Herzog H; Cohen MA; Dakin CL; Wren AM; Brynes AE; Low MJ; Ghatei MA; Cone RD; Bloom SR
    Nature; 2002 Aug; 418(6898):650-4. PubMed ID: 12167864
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Total peptide YY is a correlate of postprandial energy expenditure but not of appetite or energy intake in healthy women.
    Doucet E; Laviolette M; Imbeault P; Strychar I; Rabasa-Lhoret R; Prud'homme D
    Metabolism; 2008 Oct; 57(10):1458-64. PubMed ID: 18803953
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.